Is individualized therapy the future of lupus treatment?

摘要

The main goal of therapy for systemic lupus erythematosus is to achieve remission, as this has a major impact on patient and renal survival. Furthermore, early treatment success has been shown to improve long-term prognosis. Treatment has traditionally followed a standardized schematic therapy. However, studies have shown that treatment response may depend on age, gender, ethnicity and other genetic factors. In addition, data show that mycophenolate mofetil is effective in the treatment of lupus nephritis, and research focusing on the pathogenesis of lupus is ongoing with emerging treatment targets. Thus, the treatment of systemic lupus erythematosus and, in particular, lupus nephritis, is evolving from standardized therapy to an individualized therapeutic approach based on analysis of organ involvement, the patient’s background, risk factors and, possibly, cytokine, antibody or cell profiles.